St Vincent's Hospital Melbourne, 41 Victoria Parade Fitzroy, Victoria 3065, Australia.
Rheumatology (Oxford). 2013 Jan;52(1):155-60. doi: 10.1093/rheumatology/kes289. Epub 2012 Oct 13.
In a multi-centre study, we sought to determine whether extent of disease on high-resolution CT (HRCT) lung, reported using a simple grading system, is predictive of decline and mortality in SSc-related interstitial lung disease (SSc-ILD), independently of pulmonary function tests (PFTs) and other prognostic variables.
SSc patients with a baseline HRCT performed at the time of ILD diagnosis were identified. All HRCTs and PFTs performed during follow-up were retrieved. Demographic and disease-related data were prospectively collected. HRCTs were graded according to the percentage of lung disease: >20%: extensive; <20%: limited; unclear: indeterminate. Indeterminate HRCTs were converted to limited or extensive using a forced vital capacity threshold of 70%. The composite outcome variable was deterioration (need for home oxygen or lung transplantation), or death.
Among 172 patients followed for mean (s.d.) of 3.5 (2.9) years, there were 30 outcome events. In Weibull multivariable hazards regression modelling, baseline HRCT grade was independently predictive of outcome, with an adjusted hazard ratio (aHR) = 3.0, 95% CI 1.2, 7.5 and P = 0.02. In time-varying covariate models (based on 1309 serial PFTs and 353 serial HRCTs in 172 patients), serial diffusing capacity of the lung for carbon monoxide by alveolar volume ratio (ml/min/mmHg/l) (aHR = 0.4; 95% CI 0.3, 0.7; P = 0.001) and forced vital capacity (dl) (aHR = 0.9; 95% CI 0.8, 0.97; P = 0.008), were also strongly predictive of outcome.
Extensive disease (>20%) on HRCT at baseline, reported using a semi-quantitative grading system, is associated with a three-fold increased risk of deterioration or death in SSc-ILD, compared with limited disease. Serial PFTs are informative in follow-up of patients.
在一项多中心研究中,我们试图确定高分辨率 CT(HRCT)肺部疾病的严重程度,采用简单的分级系统报告,是否可预测系统性硬化症相关间质性肺病(SSc-ILD)的下降和死亡,而与肺功能测试(PFTs)和其他预后变量无关。
确定在ILD 诊断时进行基线 HRCT 的 SSc 患者。检索所有在随访期间进行的 HRCT 和 PFT。前瞻性收集人口统计学和疾病相关数据。根据肺部疾病的百分比对 HRCT 进行分级:>20%:广泛;<20%:局限;不确定:不确定。使用肺活量阈值为 70%将不确定的 HRCT 转换为局限或广泛。复合结局变量是恶化(需要家庭吸氧或肺移植)或死亡。
在 172 例患者中位(标准差)随访 3.5(2.9)年期间,有 30 例结局事件。在威布尔多变量风险回归模型中,基线 HRCT 分级是独立预测结局的因素,调整后的风险比(aHR)=3.0,95%CI 1.2,7.5,P=0.02。在时变协变量模型中(基于 172 例患者的 1309 次连续 PFT 和 353 次连续 HRCT),肺泡容积比弥散量(ml/min/mmHg/l)(aHR=0.4;95%CI 0.3,0.7;P=0.001)和肺活量(dl)(aHR=0.9;95%CI 0.8,0.97;P=0.008)也是结局的强烈预测因素。
与局限疾病相比,基线时 HRCT 报告的广泛疾病(>20%)与 SSc-ILD 恶化或死亡的风险增加三倍相关。连续 PFT 在患者随访中具有信息性。